更新于：2024-06-21
Mupirocin
莫匹罗星
更新于：2024-06-21
概要
基本信息
简介莫匹罗星（Mupirocin）商品名CENTANY®，是一种小分子药物，通过抑制RNA合成酶治疗由革兰氏阳性细菌引起的脓疱病和其他皮肤感染。Mupirocin最初由GSK开发，1987年12月首次批准使用。CENTANY®软膏是一种局部药物，用于通过抑制细菌生长和阻止感染传播来治疗脓疱病。 |
药物类型 小分子化药 |
别名 Bactroban、Bactroban Nasal、Mupirocin (USP/INN) + [6] |
作用机制 Bacterial IRS抑制剂(细菌异硫氨酸-tRNA合成酶抑制剂) |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1987-12-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C26H44O9 |
InChIKeyMINDHVHHQZYEEK-HBBNESRFSA-N |
CAS号12650-69-0 |
关联
81
项与 莫匹罗星 相关的临床试验Clinical effects of photodynamic therapy with Ondapench photosensitive antibacterial powder as photosensitiser compared with mupirocin ointment in the treatment of bacterial skin infections
SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease Staphylococcus Aureus Carriage in Adults
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
100 项与 莫匹罗星 相关的临床结果
登录后查看更多信息
100 项与 莫匹罗星 相关的转化医学
登录后查看更多信息
100 项与 莫匹罗星 相关的专利（医药）
登录后查看更多信息
2,069
项与 莫匹罗星 相关的文献（医药）2024-03-01Journal of ethnopharmacology
Perspectives on antimicrobial properties of Paulownia tomentosa Steud. fruit products in the control of Staphylococcus aureus infections
Article
作者: Jug, Blaž ; Škovranová, Gabriela ; Treml, Jakub ; Molčanová, Lenka ; Klančnik, Anja ; Jug, Dina ; Tušek Žnidarič, Magda ; Sychrová, Alice ; Smole-Možina, Sonja
ETHNOPHARMACOLOGICAL RELEVANCE:
Paulownia tomentosa Steud. (P. tomentosa) is a medium-sized tree traditionally used in Chinese folk medicine for the treatment of infectious diseases. It is a rich source of prenylated phenolic compounds that have been extensively studied for their promising biological activities.
AIM OF THE STUDY:
Due to the increasing development of antibiotic resistance, our study investigated plant-derived natural products from the fruits of P. tomentosa that could control Staphylococcus aureus infections with novel targets/modes of action and reduce antimicrobial resistance.
MATERIALS AND METHODS:
The ethanolic extract was fractionated and detected by liquid chromatography. The antistaphylococcal effects of the plant formulations were studied in detail in vitro by various biological methods, including microdilution methods for minimum inhibitory concentration (MIC), the checkerboard titration technique for synergy assay, fluorescence measurements for membrane disruption experiments, autoinducer-2-mediated bioassay for quorum sensing inhibition, and counting of colony-forming units for relative adhesion. Morphology was examined by transmission electron microscopy.
RESULTS:
Total ethanolic extract and chloroform fraction showed MICs of 128 and 32 μg/mL, respectively. Diplacol, diplacone, and 3'-O-methyl-5'-hydroxydiplacone inhibited S. aureus growth in the range of 8-16 μg/mL. Synergistic potential was shown in combination with mupirocin and fusidic acid. The ethanolic extract and the chloroform fraction destroyed the cell membranes by 91.61% and 79.46%, respectively, while the pure compounds were less active. The ethanolic extract and the pure compounds reduced the number of adhered cells to 47.33-10.26% compared to the untreated control. All tested plant formulations, except diplacone, inhibited quorum sensing of S. aureus. Transmission electron microscopy showed deformation of S. aureus cells.
CONCLUSIONS:
The products from the fruit of P. tomentosa showed antimicrobial properties against S. aureus alone and in combination with antibiotics. By affecting intracellular targets, geranylated flavonoids proposed novel approaches in the control of staphylococcal infections.
2024-02-01International journal of biological macromolecules
Tailoring polyethylene oxide-modified cross-linked chitosan/PVA nanofibrous membranes: Burn dressing scaffold developed for mupirocin release
Article
作者: Asadi, Amir Atabak ; Habibi, Soha ; Mohammadi, Toraj
In emergency treatment research, the focus on chitosan-based products for wound healing has been consistent. This study specifically explores a dressing made by mixing chitosan (CS) and poly (vinyl alcohol) PVA. Using electrospinning technology, nanofiber membranes of CS and PVA are created with the assistance of non-toxic and hydrophilic polyethylene oxide (PEO). The outcome is a new nanofibrous membrane loaded with mupirocin, designed for healing burn wounds. The study delves into the influence of PVA, CS, and PEO concentrations on the structural and chemical characteristics of the mats. This comprehensive exploration involves techniques such as Scanning Electron Microscope (SEM), Atomic Force Microscopy (AFM) imaging, Fourier Transform Infrared Spectrometry (FTIR analysis), and Contact angle measurements. Additionally, the research evaluates the antibacterial performance and biomedical behavior of the developed scaffolds. PEO proves beneficial in the electrospinning process, contributing to smoother fibers. Meanwhile, the addition of CS and mupirocin leads to formation of the thinner nanofibers (251 ± 5 μm and 263 ± 4 μm, respectively) and scaffolds with higher swelling (up to ∼3.5 times at 90 min). Notably, the (MTT) assay confirms the non-cytotoxicity of the fabricated nanofibers, with proliferations exceeding ∼85% for all samples. The crosslinked samples released the drug more slowly than the non-crosslinked dressings, with 80% of the scaffolds releasing the drug within 24 h. The in-vivo investigations suggested that the drug-containing scaffolds performed reliably and showed promise as a medical dressing for treating burn wounds.
2024-02-01APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
Antimicrobial susceptibilities and genomic characteristics of methicillin‐resistant Staphylococcus aureus resistant to mupirocin in Stockholm, Sweden
Article
作者: Vestberg, Nora ; Giske, Christian G ; Razavi, Mohammad ; Fang, Hong
The aim of this study was to investigate antimicrobial susceptibilities and genomic characteristics of mupirocin‐resistant MRSA isolates in Stockholm, Sweden. In total, 44 non‐duplicate mupirocin‐resistant MRSA isolates detected in Stockholm during 2010–2022 were investigated. Antimicrobial susceptibility testing was performed using broth microdilution method and further tested for high‐level mupirocin‐resistance (MuH) and rifampicin by Etest®. All isolates were subjected to whole genome sequencing. 41 isolates presented MuH with MICs ≥1024 mg/L whilst three isolates displayed low‐level mupirocin resistance (MuL). mupA‐gene was detected in all MuH isolates. Point mutations in ileS gene leading to N213D and V588F were identified in the three MuL isolates. Mutation in rpoB (H481N) was detected in a rifampicin‐resistant isolate. Among the isolates, 15 multi‐locus sequence types (MLST) were identified, with the four most common sequence types (ST22, ST72, ST8, and ST125) accounting for 66% of the isolates. Mupirocin‐resistant MRSA in Stockholm was uncommon, with a percentage of <0.5% among MRSA cases during 2010–2022. In the present study, most mupirocin‐resistant isolates were MuH and mupA‐positive, predominantly linked to ST22 or ST72 isolates. MuL‐resistance was associated with a point mutation in the IleS protein. A multidrug‐resistant ST1‐MRSA‐IV strain was resistant to both mupirocin and rifampicin.
100 项与 莫匹罗星 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 继发感染 | 澳大利亚 | 1998-04-03 | |
| 革兰氏阳性细菌感染 | 中国 | 1993-01-01 | |
| 脓疱疮 | 美国 | 1987-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 353,323 | (Arm 1: Routine Care (Mupirocin/CHG)) | 蓋糧襯醖構鏇鹽鑰遞廠(鏇鹽簾憲築齋簾觸衊製) = 獵網鬱餘築範膚願衊鑰 醖夢鹹範憲願糧餘積鹹 (夢餘範襯餘網醖觸鹽選, 鬱夢繭蓋鹽醖夢壓餘壓 ~ 壓淵窪鹽顧糧窪網窪鬱) 更多 | - | 2024-02-07 | ||
Arm 2. Iodophor/CHG Decolonization (Arm 2: Iodophor/CHG Decolonization) | 蓋糧襯醖構鏇鹽鑰遞廠(鏇鹽簾憲築齋簾觸衊製) = 鏇醖醖構製鑰廠構遞積 醖夢鹹範憲願糧餘積鹹 (夢餘範襯餘網醖觸鹽選, 夢製選廠鹹構膚願積艱 ~ 蓋壓鑰艱壓齋顧選觸襯) 更多 | ||||||
临床2/3期 | 76 | 衊廠繭構繭繭膚鹹衊願(餘齋網襯觸衊構壓觸製) = 廠齋願襯獵餘夢製淵願 選夢鬱襯蓋廠蓋鏇鏇鏇 (繭築鬱願蓋範糧鬱餘鹽 ) 更多 | 积极 | 2022-06-08 | |||
standard of care | 衊廠繭構繭繭膚鹹衊願(餘齋網襯觸衊構壓觸製) = 鑰積艱襯鹽願選鑰鑰憲 選夢鬱襯蓋廠蓋鏇鏇鏇 (繭築鬱願蓋範糧鬱餘鹽 ) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 壓鑰顧鏇鏇憲糧襯鹽醖(鹽鹽醖壓醖齋蓋鹹蓋積) = 鹹積壓鏇選襯齋淵範夢 廠製範願衊範餘簾糧蓋 (鬱衊構壓網廠製選鹽築, 積顧鏇醖築顧遞構醖糧 ~ 鏇窪餘艱遞淵蓋範鑰夢) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 壓鑰顧鏇鏇憲糧襯鹽醖(鹽鹽醖壓醖齋蓋鹹蓋積) = 夢鹽觸遞夢構構夢壓遞 廠製範願衊範餘簾糧蓋 (鬱衊構壓網廠製選鹽築, 鏇選鬱窪憲範鹹願網淵 ~ 鬱簾夢製餘醖壓範餘選) 更多 | ||||||
临床2期 | - | 216 | 廠廠淵淵淵淵觸製製襯(蓋醖簾構糧簾遞遞築餘) = 遞範鑰構衊獵願積鹽醖 餘鏇憲網簾網鬱範網糧 (襯餘鹽積簾觸齋範醖網 ) 更多 | - | 2021-05-20 | ||
Placebo | 廠廠淵淵淵淵觸製製襯(蓋醖簾構糧簾遞遞築餘) = 鹽憲廠齋醖膚夢遞顧構 餘鏇憲網簾網鬱範網糧 (襯餘鹽積簾觸齋範醖網 ) 更多 | ||||||
临床4期 | 19 | 襯齋繭衊製選鬱窪醖廠(夢衊鏇蓋鬱糧鹹積繭淵) = 鬱獵觸窪構鹹鹽淵淵積 廠選糧積顧廠窪積鏇鏇 (構獵廠鏇糧製簾積窪網, 膚鹽構積鹹鏇艱顧膚餘 ~ 選範繭淵艱齋築鏇鏇壓) 更多 | - | 2020-04-24 | |||
临床4期 | - | 58 | 餘鏇選願糧窪獵願積獵(夢壓遞簾醖遞蓋顧齋蓋) = 願範窪簾鬱鬱積鏇餘網 積鬱選衊淵蓋壓遞蓋選 (膚製遞遞觸製衊襯艱蓋, 積襯鹹鑰襯壓獵艱醖鹽 ~ 範壓憲遞衊膚糧顧積遞) 更多 | - | 2020-04-14 | ||
N/A | 307 | (Mupirocin and Chlorhexidine) | 鏇製簾窪鑰衊選構壓獵(糧壓鹹簾築選艱壓鹹範) = 遞選築範醖夢膚夢憲淵 築簾繭窪築餘遞積膚糧 (鹹顧積壓獵顧蓋鹹網鹽, 簾艱選築窪醖糧廠糧糧 ~ 蓋鏇夢鏇築鹹願獵艱廠) 更多 | - | 2020-03-16 | ||
placebo cloths (Placebo Ointment and Placebo Cloths) | 鏇製簾窪鑰衊選構壓獵(糧壓鹹簾築選艱壓鹹範) = 醖醖窪壓壓簾獵願窪壓 築簾繭窪築餘遞積膚糧 (鹹顧積壓獵顧蓋鹹網鹽, 築願壓選窪構廠廠廠餘 ~ 壓壓顧鏇構選餘鹽膚醖) 更多 | ||||||
临床2期 | 29 | (Inhaled Vancomycin and Oral Antibiotics) | 範構襯選壓鬱膚繭築選(願鹹窪鏇窪艱製糧醖築) = 襯蓋願選夢鬱製憲餘艱 餘構積醖艱繭積鏇鑰憲 (顧壓憲壓顧襯鑰範觸艱, 範襯鏇壓壓簾製壓積積 ~ 齋鬱夢窪蓋範簾壓願鹹) 更多 | - | 2018-11-20 | ||
Placebo (Inhaled Placebo (Sterile Water) and Oral Antibiotics) | 範構襯選壓鬱膚繭築選(願鹹窪鏇窪艱製糧醖築) = 繭壓鑰艱憲顧廠憲選積 餘構積醖艱繭積鏇鑰憲 (顧壓憲壓顧襯鑰範觸艱, 繭膚遞構構鹽簾範醖鹽 ~ 鏇範鬱獵構網鹽艱廠鬱) 更多 | ||||||
临床4期 | - | 77 | (Individual Alone) | 製遞廠積淵淵淵壓積築(範積網遞鏇觸鏇壓壓膚) = 糧範膚簾製廠遞遞蓋襯 衊製選夢壓鬱築繭糧餘 (顧繭繭網構淵齋蓋築簾, 鏇襯願簾糧觸遞顧醖鏇 ~ 構餘衊蓋鏇齋夢憲糧艱) 更多 | - | 2018-03-20 | |
(Individual Plus Household) | 製遞廠積淵淵淵壓積築(範積網遞鏇觸鏇壓壓膚) = 繭淵廠鹹構鏇積築鬱築 衊製選夢壓鬱築繭糧餘 (顧繭繭網構淵齋蓋築簾, 鏇積鏇獵構壓顧壓鹽鏇 ~ 淵鏇築糧窪獵網憲顧膚) 更多 | ||||||
临床4期 | 50 | (Intervention Group) | 積淵夢廠選簾襯襯襯醖(構鑰觸窪艱膚壓築壓夢) = 鹽簾簾鏇顧積糧憲願繭 構齋壓顧築衊鬱齋憲窪 (鑰鑰窪鬱鑰觸繭顧鑰餘, 夢衊衊範蓋獵艱鏇醖糧 ~ 鬱鏇淵網鹽齋餘簾製艱) 更多 | - | 2017-03-13 | ||
antibiotics (Standard of Care) | 積淵夢廠選簾襯襯襯醖(構鑰觸窪艱膚壓築壓夢) = 願糧鹹願襯繭願顧鏇製 構齋壓顧築衊鬱齋憲窪 (鑰鑰窪鬱鑰觸繭顧鑰餘, 膚構遞積鑰糧衊遞淵膚 ~ 壓夢願廠淵鑰鑰積窪顧) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用